finder.com
US
AU
NZ
UK
CA
SG
More

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy immatics biotechnologies GmbH stock

Own immatics biotechnologies GmbH stock in just a few minutes.

Jing Jun Ma
Jing Jun Ma
Fact checked
Buy immatics biotechnologies GmbH (IMTXW) Learn more

immatics biotechnologies GmbH is a business based in the US. immatics biotechnologies GmbH shares (IMTXW) are listed on the NASDAQ and all prices are listed in US Dollars. immatics biotechnologies GmbH employs 134 staff and has a market cap (total outstanding shares value) of USD$673 million.

How to buy shares in immatics biotechnologies GmbH

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for immatics biotechnologies GmbH. Find the stock by name or ticker symbol: IMTXW. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until immatics biotechnologies GmbH reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of immatics biotechnologies GmbH, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of immatics biotechnologies GmbH. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

What's in this guide?

  1. IMTXW shares summary
  2. Compare share dealing platforms
  3. Is IMTXW stock a buy or sell?
  4. Stock performance over time
  5. Can I short IMTXW shares?
  6. immatics biotechnologies GmbH's financials
  7. Does immatics biotechnologies GmbH pay a dividend?
  8. Other common questions

immatics biotechnologies GmbH share price

Use our graph to track the performance of IMTXW stocks over time.

immatics biotechnologies GmbH shares at a glance

Information last updated 2021-02-14.
52-week rangeUSD$2.29 - USD$8.49
50-day moving average USD$0
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.0785

Buy immatics biotechnologies GmbH shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Go to site
More Info
Interactive Brokers
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Go to site
More Info
Tastyworks
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Go to site
More Info
Moomoo
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
Go to site
More Info
TradeStation
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Go to site
More Info
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy immatics biotechnologies GmbH stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of immatics biotechnologies GmbH by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

immatics biotechnologies GmbH financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin -156.4%
Book value N/A
Market capitalisation USD$673 million

TTM: trailing 12 months

Shorting immatics biotechnologies GmbH shares

There are currently 3,532 immatics biotechnologies GmbH shares held short by investors – that's known as immatics biotechnologies GmbH's "short interest". This figure is 66.7% down from 10,610 last month.

There are a few different ways that this level of interest in shorting immatics biotechnologies GmbH shares can be evaluated.

immatics biotechnologies GmbH's "short interest ratio" (SIR)

immatics biotechnologies GmbH's "short interest ratio" (SIR) is the quantity of immatics biotechnologies GmbH shares currently shorted divided by the average quantity of immatics biotechnologies GmbH shares traded daily (recently around inf billion). immatics biotechnologies GmbH's SIR currently stands at 0. In other words for every 100,000 immatics biotechnologies GmbH shares traded daily on the market, roughly 0 shares are currently held short.

However immatics biotechnologies GmbH's short interest can also be evaluated against the total number of immatics biotechnologies GmbH shares, or, against the total number of tradable immatics biotechnologies GmbH shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case immatics biotechnologies GmbH's short interest could be expressed as 0% of the outstanding shares (for every 100,000 immatics biotechnologies GmbH shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable immatics biotechnologies GmbH shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against immatics biotechnologies GmbH.

Find out more about how you can short immatics biotechnologies GmbH stock.

immatics biotechnologies GmbH share dividends

We're not expecting immatics biotechnologies GmbH to pay a dividend over the next 12 months.

immatics biotechnologies GmbH overview

Immatics N.V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors through two distinct therapeutic modalities, such as Adoptive Cell Therapies and antibody-like TCR Bispecifics. Its pipeline comprises of eight therapeutic programs, of which four are in clinical trials and four are in preclinical development. The company is based in Tuebingen, Germany.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site